Icon

TEPMETKO (nda214096)- (EQ 225MG BASE)

TEPOTINIB HYDROCHLORIDE EMD SERONO INC
EQ 225MG BASE
No No
2030-Mar-19 2026-Feb-03
None None
None No
TEPMETKO is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymalepithelial transition (MET) exon 14 skipping alterations.
0 0 0
Total Other Developers None
Drugs with Suitability No
EQ 225MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.